<DOC>
	<DOCNO>NCT01850901</DOCNO>
	<brief_summary>The aim study ass whether renal denervation ( RD ) add usual care compare usual care alone reduce blood pressure ( BP ) determine ambulatory BP monitoring ( ABPM ) 6 month subject average day-time systolic BP least 135 mmHg determine use ABPM , despite use three BP lower agent document intolerance contraindication 2 4 major class antihypertensive drug ( ACEi/ARB , calcium channel blocker , betablockers diuretic ) obstruct use 3 antihypertensive Further aims assess effect renal denervation use BP lowering agent , explore effect renal denervation stratum estimate glomerular filtration rate ( eGFR ) ( eGFR 20-60 mL/min per 1.73m2 eGFR &gt; 60 mL/min per 1.73m2 ) accord baseline office BP . Randomization stratify hospital eGFR 2:1 ratio .</brief_summary>
	<brief_title>Renal Sympathetic Denervation New Treatment Therapy Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Individual mean daytime SBP ≥ 135 mmHg , determine use ABPM , use 3 antihypertensive agent least 3 month prior inclusion document intolerance 2 4 major class antihypertensive drug ( ACE/ARB , Calcium channel blocker , Beta Blocker , Diuretic ) possibility take 3 antihypertensive drug . 2 . Individual ≥18 year age . 1 . Individual unable unwilling sign inform consent . 2 . Individual treatable secondary cause hypertension . 3 . Individual eGFR 20 mL/min/1.73m2 use Modification Diet Renal Disease ( MDRD ) calculation . 4 . Individual renal artery anatomy ineligible treatment 5 . Individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study . 6 . Individual pregnant , nurse planning pregnant . 7 . Individual known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , would unlikely unable comply study followup requirement . 8 . Individual currently enrol another investigational drug device trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Renal denervation</keyword>
	<keyword>Sympathetic denervation</keyword>
</DOC>